EstroGene2.0: A multi-omic database of response to estrogens, ER-modulators, and resistance to endocrine therapies in breast cancer
Li, Z.; Chen, F.; Chen, L.; Liu, J.; Tseng, D.; Hadi, F.; Omarjee, S.; Kishore, K.; Kent, J.; Kirkpatrick, J.; DSantos, C.; Lawson, M.; Gertz, J.; Sikora, M. J.; McDonnell, D. J.; Carroll, J.; Polyak, K.; Oesterreich, S.; LEE, A. V.
Show abstract
Endocrine therapies targeting the estrogen receptor (ER/ESR1) are the cornerstone to treat ER-positive breast cancers patients, but resistance often limits their effectiveness. Understanding the molecular mechanisms is thus key to optimize the existing drugs and to develop new ER-modulators. Notable progress has been made although the fragmented way data is reported has reduced their potential impact. Here, we introduce EstroGene2.0, an expanded database of its precursor 1.0 version. EstroGene2.0 focusses on response and resistance to endocrine therapies in breast cancer models. Incorporating multi-omic profiling of 361 experiments from 212 studies across 28 cell lines, a user-friendly browser offers comprehensive data visualization and metadata mining capabilities (https://estrogeneii.web.app/). Taking advantage of the harmonized data collection, our follow-up meta-analysis revealed substantial diversity in response to different classes of ER-modulators including SERMs, SERDs, SERCA and LDD/PROTAC. Notably, endocrine resistant models exhibit a spectrum of transcriptomic alterations including a contra-directional shift in ER and interferon signaling, which is recapitulated clinically. Furthermore, dissecting multiple ESR1-mutant cell models revealed the different clinical relevance of genome-edited versus ectopic overexpression model engineering and identified high-confidence mutant-ER targets, such as NPY1R. These examples demonstrate how EstroGene2.0 helps investigate breast cancers response to endocrine therapies and explore resistance mechanisms.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Estrogen receptor alpha mutations in breast cancer cells cause gene expression changes through constant activity and through secondary effects 95%
- Hormonal regulation of Semaphorin 7a in ER+ breast cancer drives therapeutic resistance 95%
- Pan-cancer Drivers are Recurrent Transcriptional Regulatory Heterogeneities in Early-stage Luminal Breast Cancer 95%
Similar papers in this journal
- Chromatin accessibility landscape and active transcription factors in primary human invasive lobular and ductal breast carcinomas 96%
- Loss of chromosome cytoband 13q14.2 orchestrates breast cancer pathogenesis and drug response 95%
- MDM2 Inhibition in Combination with Endocrine Therapy and CDK4/6 Inhibition for the Treatment of ER-Positive Breast Cancer. 94%
Similar papers in this journal
- CRISPR/Cas9 screen reveals a role of purine synthesis for estrogen receptor α activity and tamoxifen resistance of breast cancer cells 97%
- HIRA loss transforms FH-deficient cells 95%
- Aneuploidy and deregulated DNA damage response define haploinsufficiency in breast tissues of BRCA2 mutation carriers 95%
Similar papers in this journal
Similar papers in this journal
- A cryptic transactivation domain of EZH2 binds AR and AR's splice variant promoting oncogene activation and tumorous transformation 95%
- Transcription factor RFX7 governs a tumor suppressor network in response to p53 and stress 95%
- Isoform-specific single-cell perturb-seq reveals distinct functions of alternative promoters in drug response 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.